Pfizer Eyes Xeljanz Expansion To Ulcerative Colitis
This article was originally published in The Pink Sheet Daily
Executive Summary
Two Phase III trials testing the oral JAK inhibitor in ulcerative colitis met their primary endpoints, but Pfizer is awaiting the results of another Phase III maintenance study before filing for a label extension.
You may also be interested in...
Pfizer's Xeljanz: The Slow Road To Blockbuster Status
The oral pill, perhaps best known to investors for failing to live up to initial expectations in rheumatoid arthritis, has found its groove – and new opportunities in psoriatic arthritis and ulcerative colitis are on the horizon.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.